Roswell Park received more than $21.8 million in recent competitive grants and contracts to launch new investigations or continue major research efforts. This includes funding from NCI’s Cancer Moonshot program as well as renewals for high-impact projects based at Roswell Park.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
